Amgen AMGN reported fourth-quarter 2024 adjusted ... However, weakness in some key brands like Otezla is a headwind. Also, sales of Amgen’s best-selling drugs, Prolia and Xgeva, are expected ...

We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week ...

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amgen (AMGN). But which of these two companies is the best ...

Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement ...

Amgen (NASDAQ:AMGN) shares continued gains for seven straight sessions, as the stock closed nearly 1% higher at $327.36 on Monday. The biotechnology company gained over 5% in the preceding six ...

Investors in Amgen Inc (Symbol: AMGN) saw new options become available today, for the March 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with generalized myasthenia gravis. The results ...